• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对患有VIII因子和IX因子抑制物的血友病患者进行免疫抑制治疗。

Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.

作者信息

Nilsson I M, Hedner U

出版信息

Scand J Haematol. 1976 May;16(5):369-82. doi: 10.1111/j.1600-0609.1976.tb00330.x.

DOI:10.1111/j.1600-0609.1976.tb00330.x
PMID:951577
Abstract

9 patients with severe haemophilia A and inhibitors (inhibitor levels between 0.1 to 5.8 U/ml) and 3 patients with severe haemophilia B and inhibitors (inhibitor levels between 0.1 to 11 U/ml) were treated on a total of 16 and 13 occasions, respectively, with a large dose of antigen (factor VIII or factor IX) and cyclophosphamide (10-15 mg/kg b.w. i.v. initially and then 2-3 mg/kg b.w. orally for 7-10 days) in connection with severe bleeding and surgery. All the patients had proved not to respond to treatment with factor VIII or factor IX concentrate alone, and all except one had shown strong secondary antibody increases. In 6 of the patients with haemophilia A the treatment (11 occasions) had a satisfactory haemostatic effect and even permitted neurosurgery without bleeding complications. The inhibitor level remained at zero for 5-10 days, after which it gradually began to return towards its original level. In these cases it was possible to give factor VIII in amounts which neutralised the inhibitor and afterwards raised the factor VIII initially to at least 50%. In the 3 patients with haemophilia B treatment (13 occasions) was successful except on one occasion, and surgery was performed without abnormal bleeding. The factor IX level was initially raised to at least 50% except in the one failure. The inhibitor level remained at zero for 12 days to 3 months, after which it gradually rose towards its original level. One patient was treated on 8 occasions.

摘要

9例重度甲型血友病伴抑制剂患者(抑制剂水平在0.1至5.8 U/ml之间)和3例重度乙型血友病伴抑制剂患者(抑制剂水平在0.1至11 U/ml之间)分别接受了16次和13次治疗,在严重出血和手术时,给予大剂量抗原(凝血因子VIII或凝血因子IX)和环磷酰胺(初始静脉注射10 - 15 mg/kg体重,随后口服2 - 3 mg/kg体重,持续7 - 10天)。所有患者均已证实单独使用凝血因子VIII或凝血因子IX浓缩剂治疗无效,除1例患者外,所有患者均出现了强烈的继发性抗体增加。在6例甲型血友病患者中,治疗(11次)产生了满意的止血效果,甚至允许进行神经外科手术且无出血并发症。抑制剂水平在5 - 10天内保持为零,之后逐渐开始恢复至原来水平。在这些病例中,可以给予能够中和抑制剂的凝血因子VIII量,随后最初将凝血因子VIII水平提高至至少50%。在3例乙型血友病患者中,治疗(13次)除1次外均成功,手术时未出现异常出血。除1例治疗失败外,凝血因子IX水平最初均提高至至少50%。抑制剂水平在12天至3个月内保持为零,之后逐渐上升至原来水平。1例患者接受了8次治疗。

相似文献

1
Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.对患有VIII因子和IX因子抑制物的血友病患者进行免疫抑制治疗。
Scand J Haematol. 1976 May;16(5):369-82. doi: 10.1111/j.1600-0609.1976.tb00330.x.
2
Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.通过静脉注射免疫球蛋白、环磷酰胺以及凝血因子 VIII 或 IX 联合治疗诱导血友病伴抑制剂患者的免疫耐受。
Prog Clin Biol Res. 1990;324:69-78.
3
Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.伴有因子VIII和因子IX抑制剂的血友病、发病率、出血问题及管理
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:106-12.
4
Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.150例甲型和乙型血友病患者中凝血因子VIII和IX抑制剂与ABO血型的关系
Iran J Allergy Asthma Immunol. 2006 Mar;5(1):33-4.
5
No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.在接受手术的出血性疾病患者中连续输注浓缩物后无抑制剂产生:一项前瞻性研究。
Haemophilia. 2013 May;19(3):438-44. doi: 10.1111/hae.12075. Epub 2012 Dec 20.
6
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.凝血因子VIII和IX抑制物的诊断与管理:英国血友病中心医生组织指南
Br J Haematol. 2006 Jun;133(6):591-605. doi: 10.1111/j.1365-2141.2006.06087.x.
7
The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.沙特血友病患者中凝血因子VIII和IX抑制剂的患病率:沙特全国血友病筛查项目的结果。
Medicine (Baltimore). 2017 Jan;96(2):e5456. doi: 10.1097/MD.0000000000005456.
8
Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.凝血因子(VIII、IX 和 XI)抑制剂:当前治疗实践综述。
Br J Clin Pharmacol. 2011 Oct;72(4):553-62. doi: 10.1111/j.1365-2125.2010.03899.x.
9
Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.血友病患者基线时以及在因子 VIII 和因子 IX 替代治疗期间凝血平衡的评估。
Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S135-41.
10
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.体内因子VIII和因子IX的恢复:临床环境中的个体内和个体间差异
Haemophilia. 2007 Jan;13(1):2-8. doi: 10.1111/j.1365-2516.2006.01401.x.

引用本文的文献

1
Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.血友病患者接受免疫耐受诱导方案联合免疫抑制剂以消除抑制剂的临床骨健康护理。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620913951. doi: 10.1177/1076029620913951.
2
Management of Odontogenic Fascial Space Infection in Hemophilia Patients: A Proposed Protocol.血友病患者牙源性筋膜间隙感染的管理:一项拟议方案。
J Maxillofac Oral Surg. 2019 Jun;18(2):197-202. doi: 10.1007/s12663-018-1117-0. Epub 2018 May 9.
3
"Antihemophilic factor is not the only answer for all factor VIII deficiencies." Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity.
抗血友病因子并非所有VIII因子缺乏症的唯一解决方案。一名甲型血友病患者发生牙源性感染的病例报告,该患者并发VIII因子抑制剂,并通过输注抗血友病因子和VIII因子抑制剂旁路活性进行治疗。
Indian J Dent. 2016 Sep;7(3):149-152. doi: 10.4103/0975-962X.186700.
4
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.旁路制剂治疗血友病抑制物患者的研究进展:缩小护理差距,改善治疗结局。
Ther Adv Drug Saf. 2011 Oct;2(5):213-25. doi: 10.1177/2042098611415566.
5
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.凝血因子的药代动力学:对血友病患者的临床意义
Clin Pharmacokinet. 2001;40(11):815-32. doi: 10.2165/00003088-200140110-00003.
6
Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.通过血浆置换和免疫抑制治疗联合控制一名患有抑制物的血友病患者的危及生命的出血。
Arch Dis Child. 1980 Aug;55(8):641-3. doi: 10.1136/adc.55.8.641.
7
Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.诱导高反应性血友病患者产生分裂耐受性并实现临床治愈,这些患者体内存在因子IX抗体。
Proc Natl Acad Sci U S A. 1986 Dec;83(23):9169-73. doi: 10.1073/pnas.83.23.9169.
8
Surgery of hemophiliacs--20 years' experience.血友病患者的外科手术——20年经验
World J Surg. 1977 Jan;1(1):55-66. doi: 10.1007/BF01654733.